Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

By completing this form, you agree that you have viewed our Terms & Conditions and Privacy Policy. Please note that the material contained on this Website is provided solely for informational purposes and does not constitute legal advice. The information is not guaranteed to be correct, complete, or current. Prior results also do not guarantee a similar outcome, as each case must be evaluated on its own merits. Please also note that the Information on the Website is not intended to create, and receipt or viewing does not constitute, or offer to create, an attorney-client relationship between you and Garg Law.

INSIGHTS

July 22, 2024

FDA Issues Warning Letters to Companies Selling Delta-8 THC Products in Kid-Friendly Packaging

The FDA and FTC recently issued warning letters to several companies involved in the sale of Delta-8 THC products in packaging mimicking popular national brands appealing to both children and adults, reflecting growing regulatory scrutiny over the rapidly expanding market for this cannabinoid. Delta-8 THC, a compound derived from hemp, gained popularity due to its milder psychoactive effects compared to Delta-9 THC, the primary psychoactive component of cannabis. However, the rise in Delta-8 THC products has raised significant concerns regarding safety, marketing practices, and legal compliance.

Background on Delta-8 THC

Delta-8 THC is one of over 100 cannabinoids found in the cannabis plant. It is chemically similar to Delta-9 THC but is typically derived from hemp through a chemical process that converts CBD (cannabidiol) into Delta-8 THC. The compound has been marketed as a legal alternative to Delta-9 THC, providing a similar but less intense high.

Regulatory Landscape

The legal status of Delta-8 THC is complex and varies by jurisdiction. Under the 2018 Farm Bill, hemp and its derivatives, including cannabinoids, are legal as long as they contain less than 0.3% Delta-9 THC. This has created a legal gray area for Delta-8 THC products, leading to a proliferation of these products in the market. However, with safety and health risk concerns, the FDA has not approved Delta-8 THC for any use.

FDA’s Concerns

The FDA’s warning letters highlight several key concerns about Delta-8 THC products:

  • Safety Issues: The FDA emphasized that Delta-8 THC products have not been evaluated for safety, and there is limited research on their effects. Reports of adverse events, including hallucinations, vomiting, and loss of consciousness, have raised alarm. Additionally, the conversion process from CBD to Delta-8 THC may produce harmful byproducts if not conducted properly.
  • Misleading Marketing: The FDA cited concerns about misleading marketing practices, including claims that Delta-8 THC can treat or cure various medical conditions. The FDA’s warning letters pointed out that these claims are not supported by scientific evidence and violate the Federal Food, Drug, and Cosmetic Act.
  • Child Safety: The marketing of Delta-8 THC products in forms appealing to children, such as gummies, candies, and other edibles, was a significant concern. The FDA stressed that these products pose a risk of accidental ingestion, which can be particularly dangerous for children.
  • Quality Control: The FDA noted the lack of standardized testing and quality control in the production of Delta-8 THC products. Variability in potency and the presence of contaminants, such as heavy metals and residual solvents, pose additional risks to consumers.

The FDA’s warning letters were directed at companies selling a range of Delta-8 THC products, including edibles, tinctures, and vaping products. These companies were warned to cease the sale of these products and correct any violations. The letters also served as a broader warning to the industry about the need for compliance with federal regulations. Industry response has been mixed, with some companies pledging to work with regulators to ensure that their products meet safety standards, while others have expressed concern about the impact of these warnings on their business operations. Advocacy groups have called for clearer regulations to provide guidance and ensure consumer safety.

The issuance of these warning letters indicates that the FDA is stepping up its enforcement actions against the sale of unapproved Delta-8 THC products. As the market for cannabinoids continues to evolve, regulatory oversight is likely to increase. We recommend companies in this space to prioritize compliance with federal regulations, ensure the safety and quality of their products, and avoid making unsubstantiated health claims. For consumers, these actions underscore the importance of being cautious and informed when purchasing and using Delta-8 THC products. It is crucial to buy from reputable sources, check for third-party lab testing results, and be aware of the potential risks and side effects.

 

For questions on FDA’s recent Warning Letters and/or questions on compliance and enforcement, please contact us at info@garg-law.com.

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.